Prevalence of Hepatitis (A–E) and HTLV‐I/II Infection Markers in Hemodialysis Patients of Central Greece
Identifieur interne : 005749 ( Main/Exploration ); précédent : 005748; suivant : 005750Prevalence of Hepatitis (A–E) and HTLV‐I/II Infection Markers in Hemodialysis Patients of Central Greece
Auteurs : I. Stefanidis ; E. K. Zervou [Grèce] ; C. Rizos ; C. Liaskos ; S. Zarogiannis ; V. Liakopoulos ; G. Kyriakopoulos ; G. N. DalekosSource :
- Hemodialysis International [ 1492-7535 ] ; 2004-01.
Abstract
Objective: The aim of this study was to assess the prevalence of serological and molecular markers of hepatitis (A–E) and human T‐lymphotropic viruses (HTLV) in hemodialysis (HD) patients of central Greece. Methods: 370 patients (246 males, 60 ± 14 years) attending the renal units (RUs) of central Greece (n = 5) were tested for anti‐HAV IgG, hepatitis B virus markers, anti‐HCV, anti‐HEV, and anti‐HTLV‐I/II with ELISA. In 131 casual samples, regardless of anti‐HCV status, a sensitive, qualitative HCV‐RNA assay (Versant®, Bayer) based on transcription‐mediated amplification (TMA) was applied. Results: Previous HBV infection (anti‐HBc) was found in 48% and current HBV infection in 5.5% (HbsAg) of the patients. Anti‐HAV was detected in 94% while anti‐HDV and anti‐HTLV were negative. Anti‐HCV prevalence was 23% varying from 11 to 36% in the different RUs. Frequency of anti‐HEV (4.1%) was also highly varying (1.4–9.8%). There was no association between the infection markers and age, sex, or history of transfusion. Anti‐HCV correlated with duration of HD. HCV‐RNA was detected in 44/131 samples. In 15 cases results of anti‐HCV and TMA were contradicting. Two anti‐HCV negative samples were HCV‐RNA positive (2.3%). Conclusion: In RUs of central Greece, a high prevalence of HCV infection was found, associated with the duration of HD. The high prevalence of anti‐HEV found in 1 RU must be investigated further. In some of anti‐HCV‐negative patients viremia was detected. This result indicates that a considerable number of HCV infections are serologically occult. HCV‐RNA testing, regardless of the anti‐HCV status, has to be considered seriously in HD patients.
Url:
DOI: 10.1111/j.1492-7535.2004.0085bh.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001400
- to stream Istex, to step Curation: 001400
- to stream Istex, to step Checkpoint: 001E27
- to stream Main, to step Merge: 005B95
- to stream Main, to step Curation: 005749
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prevalence of Hepatitis (A–E) and HTLV‐I/II Infection Markers in Hemodialysis Patients of Central Greece</title><author><name sortKey="Stefanidis, I" sort="Stefanidis, I" uniqKey="Stefanidis I" first="I." last="Stefanidis">I. Stefanidis</name></author><author><name sortKey="Zervou, E K" sort="Zervou, E K" uniqKey="Zervou E" first="E. K." last="Zervou">E. K. Zervou</name></author><author><name sortKey="Rizos, C" sort="Rizos, C" uniqKey="Rizos C" first="C." last="Rizos">C. Rizos</name></author><author><name sortKey="Liaskos, C" sort="Liaskos, C" uniqKey="Liaskos C" first="C." last="Liaskos">C. Liaskos</name></author><author><name sortKey="Zarogiannis, S" sort="Zarogiannis, S" uniqKey="Zarogiannis S" first="S." last="Zarogiannis">S. Zarogiannis</name></author><author><name sortKey="Liakopoulos, V" sort="Liakopoulos, V" uniqKey="Liakopoulos V" first="V." last="Liakopoulos">V. Liakopoulos</name></author><author><name sortKey="Kyriakopoulos, G" sort="Kyriakopoulos, G" uniqKey="Kyriakopoulos G" first="G." last="Kyriakopoulos">G. Kyriakopoulos</name></author><author><name sortKey="Dalekos, G N" sort="Dalekos, G N" uniqKey="Dalekos G" first="G. N." last="Dalekos">G. N. Dalekos</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0A553DA490BEC43415E2F4F409C0D26E5132D7CE</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1111/j.1492-7535.2004.0085bh.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-89KLVWPQ-G/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001400</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001400</idno><idno type="wicri:Area/Istex/Curation">001400</idno><idno type="wicri:Area/Istex/Checkpoint">001E27</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001E27</idno><idno type="wicri:doubleKey">1492-7535:2004:Stefanidis I:prevalence:of:hepatitis</idno><idno type="wicri:Area/Main/Merge">005B95</idno><idno type="wicri:Area/Main/Curation">005749</idno><idno type="wicri:Area/Main/Exploration">005749</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Prevalence of Hepatitis (A–E) and HTLV‐I/II Infection Markers in Hemodialysis Patients of Central Greece</title><author><name sortKey="Stefanidis, I" sort="Stefanidis, I" uniqKey="Stefanidis I" first="I." last="Stefanidis">I. Stefanidis</name><affiliation><wicri:noCountry code="subField">Larissa</wicri:noCountry></affiliation></author><author><name sortKey="Zervou, E K" sort="Zervou, E K" uniqKey="Zervou E" first="E. K." last="Zervou">E. K. Zervou</name><affiliation wicri:level="1"><country xml:lang="fr">Grèce</country><wicri:regionArea>Blood Bank at the University Hospital of Ioannina</wicri:regionArea></affiliation></author><author><name sortKey="Rizos, C" sort="Rizos, C" uniqKey="Rizos C" first="C." last="Rizos">C. Rizos</name><affiliation><wicri:noCountry code="subField">Larissa</wicri:noCountry></affiliation></author><author><name sortKey="Liaskos, C" sort="Liaskos, C" uniqKey="Liaskos C" first="C." last="Liaskos">C. Liaskos</name><affiliation><wicri:noCountry code="subField">Larissa</wicri:noCountry></affiliation></author><author><name sortKey="Zarogiannis, S" sort="Zarogiannis, S" uniqKey="Zarogiannis S" first="S." last="Zarogiannis">S. Zarogiannis</name><affiliation><wicri:noCountry code="subField">Larissa</wicri:noCountry></affiliation></author><author><name sortKey="Liakopoulos, V" sort="Liakopoulos, V" uniqKey="Liakopoulos V" first="V." last="Liakopoulos">V. Liakopoulos</name><affiliation><wicri:noCountry code="subField">Larissa</wicri:noCountry></affiliation></author><author><name sortKey="Kyriakopoulos, G" sort="Kyriakopoulos, G" uniqKey="Kyriakopoulos G" first="G." last="Kyriakopoulos">G. Kyriakopoulos</name><affiliation><wicri:noCountry code="subField">Larissa</wicri:noCountry></affiliation></author><author><name sortKey="Dalekos, G N" sort="Dalekos, G N" uniqKey="Dalekos G" first="G. N." last="Dalekos">G. N. Dalekos</name><affiliation><wicri:noCountry code="subField">Larissa</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Hemodialysis International</title><title level="j" type="alt">HEMODIALYSIS INTERNATIONAL</title><idno type="ISSN">1492-7535</idno><idno type="eISSN">1542-4758</idno><imprint><biblScope unit="vol">8</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="101">101</biblScope><biblScope unit="page" to="101">101</biblScope><biblScope unit="page-count">100</biblScope><publisher>Blackwell Science Inc</publisher><pubPlace>Oxford, UK; Malden, USA</pubPlace><date type="published" when="2004-01">2004-01</date></imprint><idno type="ISSN">1492-7535</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1492-7535</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: The aim of this study was to assess the prevalence of serological and molecular markers of hepatitis (A–E) and human T‐lymphotropic viruses (HTLV) in hemodialysis (HD) patients of central Greece. Methods: 370 patients (246 males, 60 ± 14 years) attending the renal units (RUs) of central Greece (n = 5) were tested for anti‐HAV IgG, hepatitis B virus markers, anti‐HCV, anti‐HEV, and anti‐HTLV‐I/II with ELISA. In 131 casual samples, regardless of anti‐HCV status, a sensitive, qualitative HCV‐RNA assay (Versant®, Bayer) based on transcription‐mediated amplification (TMA) was applied. Results: Previous HBV infection (anti‐HBc) was found in 48% and current HBV infection in 5.5% (HbsAg) of the patients. Anti‐HAV was detected in 94% while anti‐HDV and anti‐HTLV were negative. Anti‐HCV prevalence was 23% varying from 11 to 36% in the different RUs. Frequency of anti‐HEV (4.1%) was also highly varying (1.4–9.8%). There was no association between the infection markers and age, sex, or history of transfusion. Anti‐HCV correlated with duration of HD. HCV‐RNA was detected in 44/131 samples. In 15 cases results of anti‐HCV and TMA were contradicting. Two anti‐HCV negative samples were HCV‐RNA positive (2.3%). Conclusion: In RUs of central Greece, a high prevalence of HCV infection was found, associated with the duration of HD. The high prevalence of anti‐HEV found in 1 RU must be investigated further. In some of anti‐HCV‐negative patients viremia was detected. This result indicates that a considerable number of HCV infections are serologically occult. HCV‐RNA testing, regardless of the anti‐HCV status, has to be considered seriously in HD patients.</div></front></TEI><affiliations><list><country><li>Grèce</li></country></list><tree><noCountry><name sortKey="Dalekos, G N" sort="Dalekos, G N" uniqKey="Dalekos G" first="G. N." last="Dalekos">G. N. Dalekos</name><name sortKey="Kyriakopoulos, G" sort="Kyriakopoulos, G" uniqKey="Kyriakopoulos G" first="G." last="Kyriakopoulos">G. Kyriakopoulos</name><name sortKey="Liakopoulos, V" sort="Liakopoulos, V" uniqKey="Liakopoulos V" first="V." last="Liakopoulos">V. Liakopoulos</name><name sortKey="Liaskos, C" sort="Liaskos, C" uniqKey="Liaskos C" first="C." last="Liaskos">C. Liaskos</name><name sortKey="Rizos, C" sort="Rizos, C" uniqKey="Rizos C" first="C." last="Rizos">C. Rizos</name><name sortKey="Stefanidis, I" sort="Stefanidis, I" uniqKey="Stefanidis I" first="I." last="Stefanidis">I. Stefanidis</name><name sortKey="Zarogiannis, S" sort="Zarogiannis, S" uniqKey="Zarogiannis S" first="S." last="Zarogiannis">S. Zarogiannis</name></noCountry><country name="Grèce"><noRegion><name sortKey="Zervou, E K" sort="Zervou, E K" uniqKey="Zervou E" first="E. K." last="Zervou">E. K. Zervou</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005749 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005749 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0A553DA490BEC43415E2F4F409C0D26E5132D7CE
|texte= Prevalence of Hepatitis (A–E) and HTLV‐I/II Infection Markers in Hemodialysis Patients of Central Greece
}}
| This area was generated with Dilib version V0.6.33. |  |